Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
11 01 2022
Historique:
received: 22 02 2021
accepted: 03 06 2021
pubmed: 8 9 2021
medline: 11 3 2022
entrez: 7 9 2021
Statut: ppublish

Résumé

Patient-reported outcomes (PROs) are relevant and valuable end points in the care of patients with myelodysplastic syndromes (MDS). However, a consensus-based selection of PROs for MDS, derived by both patients and hematologists, is lacking. We aimed to develop a core set of PROs for patients with MDS as part of the prospective European LeukemiaNet MDS (EUMDS) Registry. According to international guidelines, candidate PROs were identified from a comprehensive literature search of MDS studies. Overall, 40 PROs were selected and evaluated in a two-round Delphi survey by 40 patients with MDS and 38 hematologists in the first round and 38 patients and 32 hematologists in the second round. Based on an agreement scale and predefined inclusion criteria, both patients and hematologists selected "general quality of life" as a core PRO. Hematologists also selected "transfusion-dependency burden" and "ability to work/activities of daily living" as core PROs. The second Delphi round increased PRO rating agreements. Statistically significant rating differences between patients and hematologists were observed for 28 PROs (Mann-Whitney U test; P < .05) in the first round and for 19 PROs in the second round, with "disease knowledge" and "confidence in health care services" rated notably higher by patients. The overall mean PRO ratings correlation between the 2 groups was moderate (Spearman's rank correlation coefficient = 0.5; P < .05). This first consensus on a core set of PROs jointly developed by patients and hematologists forms the basis for patient-centered care in daily practice and clinical research.

Identifiants

pubmed: 34492684
pii: S2473-9529(21)00511-5
doi: 10.1182/bloodadvances.2021004568
pmc: PMC8753222
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Informations de copyright

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Arch Clin Neuropsychol. 2016 Sep;31(6):506-16
pubmed: 27475282
Leuk Res. 2011 Dec;35(12):1591-6
pubmed: 21708407
Blood. 2017 Aug 17;130(7):859-866
pubmed: 28694324
Soc Sci Med. 2009 Aug;69(3):307-16
pubmed: 19520474
Braz J Phys Ther. 2016 Jan 19;20(2):105-13
pubmed: 26786084
J Epidemiol Community Health. 2005 May;59(5):342-5
pubmed: 15831678
Trials. 2014 Jun 25;15:247
pubmed: 24962012
Trials. 2014 Feb 05;15:49
pubmed: 24495582
Haematologica. 2013 Jun;98(6):828-30
pubmed: 23729723
Orphanet J Rare Dis. 2020 Sep 17;15(1):249
pubmed: 32943103
JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
Leuk Res. 2015 Aug;39(8):859-65
pubmed: 26120100
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Leukemia. 2020 Sep;34(9):2451-2459
pubmed: 32086447
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87
pubmed: 28040720
Br J Haematol. 2015 Aug;170(3):372-83
pubmed: 25907546
Blood. 2019 Mar 7;133(10):1020-1030
pubmed: 30404811
Leuk Res. 2008 May;32(5):691-8
pubmed: 18054795
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
Oncol Rev. 2018 Jul 04;12(2):374
pubmed: 30283608
Value Health. 2013 Dec;16(8):1150-5
pubmed: 24326168
JAMA Oncol. 2015 Jun;1(3):375-9
pubmed: 26181187
Br J Haematol. 2020 Nov;191(3):405-417
pubmed: 32410281
Br J Haematol. 2015 Feb;168(3):361-70
pubmed: 25272332
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
Haematologica. 2016 Jun;101(6):781-8
pubmed: 26944474
J Clin Oncol. 2002 Jul 15;20(14):3182-3; author reply 3183-4
pubmed: 12118036
Br J Haematol. 2020 Apr;189(2):279-290
pubmed: 31960409
JAMA Oncol. 2017 Aug 1;3(8):1043-1050
pubmed: 28208174
Curr Hematol Malig Rep. 2017 Oct;12(5):455-460
pubmed: 28822056
Anemia. 2016;2016:8494738
pubmed: 27195147
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
PLoS One. 2008 Aug 28;3(8):e3081
pubmed: 18769481
J Patient Rep Outcomes. 2019 Jun 19;3(1):35
pubmed: 31218454
Oncologist. 2011;16(6):904-11
pubmed: 21478277
Am J Blood Res. 2012;2(2):136-47
pubmed: 22762033
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Lancet Oncol. 2018 May;19(5):e267-e274
pubmed: 29726391
Cancer Med. 2019 Feb;8(2):543-553
pubmed: 30632713
Expert Rev Hematol. 2009 Feb;2(1):69-80
pubmed: 21082996
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559
Cancer Nurs. 2013 Nov-Dec;36(6):E1-E16
pubmed: 23047799
Lancet Oncol. 2015 Nov;16(15):1506-1514
pubmed: 26404501
Eur J Haematol. 2020 May;104(5):476-487
pubmed: 31985078
JAMA. 2013 Feb 27;309(8):814-22
pubmed: 23443445
Blood. 2014 Jan 16;123(3):451-2
pubmed: 24434998
Blood Adv. 2020 Aug 25;4(16):4029-4044
pubmed: 32841339
Ann Hematol. 2012 Sep;91(9):1333-43
pubmed: 22547053
Value Health. 2019 Feb;22(2):203-209
pubmed: 30711065
Leukemia. 2018 Jun;32(6):1380-1392
pubmed: 29572506
Blood. 2000 Dec 1;96(12):3671-4
pubmed: 11090046
Eur J Cancer. 2016 Apr;57:68-77
pubmed: 26886181
J Clin Epidemiol. 2020 Sep;125:206-212.e1
pubmed: 31945480

Auteurs

Igor Stojkov (I)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.

Annette Conrads-Frank (A)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.

Ursula Rochau (U)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.

Karin A Koinig (KA)

Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.

Marjan Arvandi (M)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.

Sibylle Puntscher (S)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.

Corine van Marrewijk (C)

Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Pierre Fenaux (P)

Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France.

Argiris Symeonidis (A)

Department of Medicine, Division Hematology, University of Patras Medical School, Patras, Greece.

Fatiha Chermat (F)

Groupe Francophone des Myélodysplasies (GFM), Paris, France.

Hege Garelius (H)

Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.

David Bowen (D)

St James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom.

Moshe Mittelman (M)

Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel.

Elvira Mora (E)

Hospital Universitario y Politécnico La Fe.
Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Theo de Witte (T)

Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Fabio Efficace (F)

Health Outcomes Research Unit, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Rome, Italy.

Uwe Siebert (U)

Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria.
Center for Health Decision Science, Department of Health Policy and Management, Harvard Chan School of Public Health, Boston, MA; and.
Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Reinhard Stauder (R)

Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH